Hypertension is the most common cardiovascular disease， is the world's major public health With the increased incidence of hypertension and the hypertension research， development of antihypertensive drugs currently has made great From the 1940s onwards in the 19th century， antihypertensive drugs has undergone a major transformation， the earliest of the sympathetic ganglia blockers， diuretics， beta-blockers， calcium channel blockers， to act on drug RASS system angiotensin-converting enzyme inhibitor (ACEI) or Angiotensin II receptor blockers (ARB)， step by step and the cancer struggle with high blood pressure， type of antihypertensive drugs are constantly being Renin inhibitor (RI) renin inhibitor， is Novartis (Novartis AG) the latest research and development of a class of antihypertensive drugs， in 2007， FDA approval， the trade name Tekturna， which start sites in Renin， direct from the source rennin， theoretically， Renin inhibitor long-term application does not cause plasma Renin activity (PRA) feedback， not only can better control blood pressure， but also to prevent or reverse the target organ damage and cardiovascular diseases provides a new [Keywords] hypertension antihypertensive new aliji LUN Renin inhibitors
